Skip to main content

Agilent, IDT Ally to Offer Oligo Synthesis Services to Pharmas

NEW YORK (GenomeWeb News) - Agilent Technologies and Integrated DNA Technologies will jointly offer oligo synthesis and other products and services to create a "complete development pathway" for drug developers, the companies said yesterday.
 
The companies said they will provide reciprocal referrals for synthetic oligonucleotides and will offer chemical and analytical services designed to help customers reduce time and costs associated with moving from research to clinical development.
 
Under the agreement, IDT will produce small-scale and mid-scale products for use in research and drug screening, while Agilent's Nucleic Acid Solutions division will contribute large-scale quantities of oligos to be used as active pharmaceutical ingredients in clinical trials and drug manufacturing.
 
IDT's COO, Trey Martin, said the agreement allows the companies to offer "a bench-to-bedside oligonucleotide manufacturing package," that includes "harmonized manufacturing methods from basic research scales through API manufacturing."

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.